Patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 should not use these medications, as studies in rodents have shown an increased risk of thyroid C-cell tumours (though the relevance to humans remains uncertain)
But women with PCOS who meet the BMI eligibility criteria (BMI 27+ with a metabolic comorbidity, or BMI 30+) can access both through private prescription
Research suggests that adding growth hormone pathway support during aggressive weight loss can reduce lean mass loss from 35% of total weight lost down to 10-15%
Identity Verification : Every batch is verified through analytical testing to confirm the active GSH form, distinguishing it from oxidized GSSG and ensuring maximum bioactive potential
Reference: Lhteenvuo M, Tiihonen J, Solismaa A, Tanskanen A, Mittendorfer-Rutz E, Taipale H